Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Thousand Oaks Biologics Inc. ("TOBio") is an active China-based CDMO specializing in the development and contract manufacturing of biologic drugs including mAbs, BsAbs, ADCs, Fc fusion proteins and other recombinant protein products. The company has delivered nearly 100 CMC projects since its founding in 2017—including successful preapproval inspections—and offers end-to-end solutions from cell line development through IND/NDA filing to commercial production. TOBio’s facilities meet US FDA/EU EMA/China NMPA standards.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Thousand Oaks Biologics Inc..